-
Huang Guo meets with heads of drug regulatory authorities of UK, Brazil, Indonesia
2026-09-30
On Sept 19, Huang Guo, commissioner of China's National Medical Products Administration (NMPA), met in Beijing with Lawrence Tallon, chief executive of the UK's Medicines and Healthcare Products Regulatory Agency, Leandro Pinheiro Safatle, director-president of Brazil's National Health Surveillance Agency, Taruna Ikrar, head of Indonesia's Food and Drug Authority (BPOM), and William Adi Teja, deputy I of the BPOM.
-
NMPA signs letter of intent for cooperation with UK’s MHRA
2026-09-30
From Sept 21 to 24, Huang Guo, commissioner of China's National Medical Products Administration (NMPA), led a delegation to the UK for a working visit at the invitation of the British side, in an effort to implement the consensus reached by the leaders of China and the UK and strengthen exchanges and cooperation in pharmaceutical regulation between the two countries.
-
Yang Sheng meets with delegation of Egyptian Drug Authority
2026-09-30
Yang Sheng, deputy commissioner of China's National Medical Products Administration (NMPA), met with a delegation from the Egyptian Drug Authority (EDA) on Sept 28 in Beijing.
-
Lei Ping meets with chief executive of Malaysia’s Medical Device Authority
2026-09-30
Lei Ping, deputy commissioner of China's National Medical Products Administration (NMPA), met with Muralitharan Paramasua, chief executive of the Medical Device Authority of Malaysia, on Sept 22 in Beijing.
-
Huang Guo meets with president of Global Health at Gates Foundation
2026-09-23
Huang Guo, commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Trevor Mundel, president of Global Health at the Gates Foundation, on Sept 15 in Beijing.
-
NMPA conducts management review of QMS for regulation of vaccine and drug GMP compliance
2026-07-10
The National Medical Products Administration (NMPA) conducted its 2025 annual management review of the Quality Management System (QMS) for regulation of vaccine and drug Good Manufacturing Practice (GMP) compliance on June 30. NMPA Commissioner Huang Guo presided over the meeting and fully affirmed the suitability, adequacy and effectiveness of the NMPA's QMS in both areas.
